|
Fatty-Acid Modified Cytotoxins and Peptides for Improved Efficacy, Safety, and Dosing Flexibility
SHORT DESCRIPTION
A suite of four complementary technologies for a long-chain fatty‑acid–guided drug delivery platform to achieve superior therapeutic outcomes with reduced toxicity across both oncology and critical care applications.
INVENTORS
Nathan Gianneschi*, and others
Weinberg College of Arts and Sciences,...
Published: 6/2/2026
|
Updated: 6/1/2026
|
Inventor(s):
Keywords(s): Adjunct therapy, BIO2026, Biologic, Breast cancer, Cancer/Oncology, Chemotherapy, Colon cancer, Lung cancer, Ovarian cancer, Pancreatic cancer, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Aqueous Formulations of Cytotoxic Taxanes with Cyclodextrin
NU 2022-109
INVENTORS
Brittney Williams
Matthew Thompson
Nathan Gianneschi*
SHORT DESCRIPTION
This invention describes aqueous formulations of cytotoxic taxane drugs conjugated to fatty acids, solubilized using cyclodextrin inclusion complexes, providing water-soluble chemotherapy formulations that eliminate the need for toxic organic solvents...
Published: 6/16/2026
|
Updated: 2/25/2026
|
Inventor(s):
Keywords(s): BIO2026, Cancer/Oncology, Chemotherapy, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Modified Cytotoxins and their Therapeutic Use
NU 2022-111
INVENTORS
Cassandra Callmann
Matthew Thompson
Clare LeGuyader
Paul Bertin
Nathan Gianneschi*
SHORT DESCRIPTION
This invention is for chemically modified small-molecule cytotoxic drugs conjugated to long-chain fatty acid-like hydrophobic moieties that bind non-covalently to albumin, creating improved cancer therapeutics with enhanced...
Published: 6/16/2026
|
Updated: 2/24/2026
|
Inventor(s):
Keywords(s): BIO2026, Cancer/Oncology, Chemotherapy, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity
SHORT DESCRIPTION
A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists.
INVENTORS
Paul W Burridge*, PhD
Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine
* Principal Investigator
NU...
Published: 2/6/2026
|
Updated: 2/6/2026
|
Inventor(s):
Keywords(s): Cancer Treatment, Cancer/Oncology, Cardiology and Cardiovascular disease, Chemotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|